###begin article-title 0
TSC-mTOR maintains quiescence and function of hematopoietic stem cells by repressing mitochondrial biogenesis and reactive oxygen species
###end article-title 0
###begin p 1
###xml 26 40 26 40 <email xmlns:xlink="http://www.w3.org/1999/xlink">panz@umich.edu</email>
###xml 54 69 54 69 <email xmlns:xlink="http://www.w3.org/1999/xlink">yangl@umich.edu</email>
CORRESPONDENCE Pan Zheng: panz@umich.edu OR Yang Liu: yangl@umich.edu
###end p 1
###begin p 2
This article is distributed under the terms of an Attribution-Noncommercial-Share Alike-No Mirror Sites license for the first six months after the publication date (see ). After six months it is available under a Creative Commons License (Attribution-Noncommercial-Share Alike 3.0 Unported license, as described at ).
###end p 2
###begin p 3
###xml 157 161 157 161 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tsc1</italic>
###xml 276 280 276 280 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tsc1</italic>
The tuberous sclerosis complex (TSC)-mammalian target of rapamycin (mTOR) pathway is a key regulator of cellular metabolism. We used conditional deletion of Tsc1 to address how quiescence is associated with the function of hematopoietic stem cells (HSCs). We demonstrate that Tsc1 deletion in the HSCs drives them from quiescence into rapid cycling, with increased mitochondrial biogenesis and elevated levels of reactive oxygen species (ROS). Importantly, this deletion dramatically reduced both hematopoiesis and self-renewal of HSCs, as revealed by serial and competitive bone marrow transplantation. In vivo treatment with an ROS antagonist restored HSC numbers and functions. These data demonstrated that the TSC-mTOR pathway maintains the quiescence and function of HSCs by repressing ROS production. The detrimental effect of up-regulated ROS in metabolically active HSCs may explain the well-documented association between quiescence and the "stemness" of HSCs.
###end p 3
###begin p 4
###xml 154 155 154 155 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 158 159 158 159 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 164 165 164 165 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 170 171 170 171 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 252 253 252 253 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
Abbreviations used: BMT, BM transplantation; CBC, complete blood cell count; Ctrl, control; DCF-DA, 2',7'-dichlorodihydrofluorescein diacetate; FLSK, Flt2-Lin-Sca-1+c-Kit+; HSC, hematopoietic stem cell; LT-HSC, long-term HSC; mTOR, mammalian TOR; NAC, N-acetylcysteine; PI3K, phosphoinositide 3-kinase; pIpC, polyinosine-polycytidine; ROS, reactive oxygen species; TOR, target of rapamycin; TSC, tuberous sclerosis complex; WBM, whole BM.
###end p 4
###begin p 5
###xml 161 162 161 162 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib1">1</xref>
###xml 163 164 163 164 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib6">6</xref>
###xml 297 298 297 298 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib4">4</xref>
###xml 332 335 332 335 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p21</italic>
###xml 337 338 337 338 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib5">5</xref>
###xml 344 348 344 348 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pten</italic>
###xml 350 351 350 351 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib6">6</xref>
###xml 550 551 550 551 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib4">4</xref>
###xml 552 553 552 553 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib6">6</xref>
A long-standing but poorly understood observation in stem cell biology is that the quiescence of the adult stem cells associates with their long-term functions (1-6). The molecular pathway that keeps them in quiescence is largely obscure, although recent studies have implicated stem cell niches (4) and cell-intrinsic functions of p21 (5) and Pten (6) in this process. The significance of quiescence in stem cell function is bolstered as genetic disruption of its quiescence almost invariably inactivates the hematopoietic stem cell (HSC) function (4-6). Nevertheless, it is largely unclear how an active metabolism is incompatible with a normal HSC function.
###end p 5
###begin p 6
###xml 175 176 175 176 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib7">7</xref>
###xml 177 178 177 178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib9">9</xref>
###xml 254 256 254 256 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib10">10</xref>
###xml 257 259 257 259 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib15">15</xref>
In addition to cell-intrinsic factors, accumulating data demonstrated that residence of adult HSCs in the BM niches is essential for their quiescence and long-term functions (7-9). Because exposure to high levels of oxygen damages the functions of HSCs (10-15), it has been proposed that hypoxia is important for HSC functions. However, the underlying molecular mechanism of how hypoxia maintains the stemness is unknown.
###end p 6
###begin p 7
###xml 3 13 3 13 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Drosophila</italic>
###xml 202 204 202 204 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib16">16</xref>
###xml 205 207 205 207 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib20">20</xref>
###xml 3 13 <span type="species:ncbi:7227">Drosophila</span>
In Drosophila and in vitro-cultured mammalian cells, hypoxia activates tuberous sclerosis complex (TSC), which can inhibit the target of rapamycin (TOR), through REDD1 and AMP-activated protein kinase (16-20). Whether this pathway operates in the HSCs has yet to be tested.
###end p 7
###begin p 8
###xml 256 258 256 258 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib21">21</xref>
###xml 375 377 375 377 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib22">22</xref>
###xml 379 381 379 381 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib23">23</xref>
###xml 525 527 521 523 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib24">24</xref>
###xml 777 781 773 777 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pten</italic>
###xml 929 930 925 926 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib6">6</xref>
###xml 932 934 928 930 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib25">25</xref>
###xml 1054 1056 1050 1052 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib26">26</xref>
The mammalian TOR (mTOR) pathway has emerged as a key regulator for cellular metabolism. Accumulating data have demonstrated that mTOR regulates several important cellular functions, including protein synthesis, autophagy, endocytosis and nutrient uptake (21). An increased mTOR activity results in increased cellular growth and nonmalignant growth of cells in solid organs (22, 23). Recently, it has been demonstrated that mTOR controls the mitochondrial oxidative function through a YY1-PGC-1alpha transcriptional complex (24). Although systemic analysis of the mTOR pathway in the function of HSCs has not been performed, several lines of evidence are consistent with a critical role for the pathway in HSC function. First, two groups reported that the targeted mutation of Pten, a negative regulator of phosphoinositide 3-kinase (PI3K) and AKT, which are inhibitors for TSC function, reduced long-term HSC (LT-HSC) function (6, 25). Second, up-regulated mTOR activity is associated with a higher level of intracellular reactive oxygen species (ROS) (26). Nevertheless, because these regulators have multiple functions, the link between the mTOR pathway and HSCs remains tentative.
###end p 8
###begin p 9
###xml 148 152 148 152 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TSC1</italic>
###xml 157 161 157 161 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TSC2</italic>
###xml 163 165 163 165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib27">27</xref>
###xml 167 169 167 169 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib28">28</xref>
###xml 193 203 193 203 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Drosophila</italic>
###xml 267 269 267 269 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib29">29</xref>
###xml 271 273 271 273 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib30">30</xref>
###xml 353 355 353 355 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib31">31</xref>
###xml 357 359 357 359 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib32">32</xref>
###xml 387 389 387 389 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib33">33</xref>
###xml 93 101 <span type="species:ncbi:9606">patients</span>
###xml 193 203 <span type="species:ncbi:7227">Drosophila</span>
TSC was first defined by genetic mutations leading to nonmalignant growth in solid organs in patients with genetic lesions of two genes, now called TSC1 and TSC2 (27, 28). Genetic screening in Drosophila demonstrated that the TSC determined the size of solid organs (29, 30). More recently, TSC has emerged as the major negative regulator for the mTOR (31, 32) (for review see reference 33).
###end p 9
###begin p 10
###xml 60 64 60 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TSC1</italic>
###xml 151 155 151 155 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tsc1</italic>
In this paper, we demonstrate that the targeted mutation of TSC1 disrupts quiescence and long-term functions of the HSCs. Moreover, we showed that the Tsc1 defect leads to increased mitochondrion biogenesis and accumulation of ROS, and that the HSC defects can be largely restored by blocking ROS activity in vivo. Collectively, our data demonstrated that the TSC-mTOR pathway controls quiescence and functions of HSCs by repressing ROS production.
###end p 10
###begin title 11
RESULTS
###end title 11
###begin title 12
TSC1 controls quiescence of HSCs
###end title 12
###begin p 13
###xml 103 109 103 109 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MX-Cre</italic>
###xml 121 125 121 125 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tsc1</italic>
###xml 266 271 266 271 <sup xmlns:xlink="http://www.w3.org/1999/xlink">fl/fl</sup>
###xml 279 280 279 280 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 262 280 262 280 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tsc1<sup>fl/fl</sup>mx-1-cre<sup>+</sup></italic>
###xml 293 298 293 298 <sup xmlns:xlink="http://www.w3.org/1999/xlink">fl/fl</sup>
###xml 306 307 306 307 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 289 307 289 307 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tsc1<sup>fl/fl</sup>mx-1-cre<sup>&#8722;</sup></italic>
###xml 379 383 379 383 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tsc1</italic>
###xml 489 493 489 493 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tsc1</italic>
###xml 522 527 522 527 <sup xmlns:xlink="http://www.w3.org/1999/xlink">fl/fl</sup>
###xml 535 536 535 536 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 518 536 518 536 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tsc1<sup>fl/fl</sup>mx-1-cre<sup>+</sup></italic>
###xml 550 554 550 554 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tsc1</italic>
###xml 574 575 574 575 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 578 579 578 579 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 584 585 584 585 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 590 591 590 591 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 603 604 603 604 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 614 616 614 616 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib34">34</xref>
###xml 627 632 627 632 <sup xmlns:xlink="http://www.w3.org/1999/xlink">fl/fl</sup>
###xml 640 641 640 641 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 623 641 623 641 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tsc1<sup>fl/fl</sup>mx-1-cre<sup>+</sup></italic>
###xml 707 715 707 715 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 a</xref>
###xml 833 837 833 837 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tsc1</italic>
###xml 902 910 890 898 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 b</xref>
###xml 939 943 927 931 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tsc1</italic>
###xml 1026 1031 1014 1019 <sup xmlns:xlink="http://www.w3.org/1999/xlink">fl/fl</sup>
###xml 1039 1040 1027 1028 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1022 1040 1010 1028 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tsc1<sup>fl/fl</sup>mx-1-cre<sup>+</sup></italic>
###xml 80 84 <span type="species:ncbi:10090">mice</span>
###xml 325 329 <span type="species:ncbi:10090">mice</span>
###xml 537 541 <span type="species:ncbi:10090">mice</span>
###xml 642 646 <span type="species:ncbi:10090">mice</span>
###xml 1041 1045 <span type="species:ncbi:10090">mice</span>
To address the function of mTOR activation in the biology of HSCs, we generated mice that express both MX-Cre and floxed Tsc1 locus and used polyinosine-polycytidine (pIpC) treatment to induce deletion of TSC in the HSCs. Starting at 6 wk of age, we treated the Tsc1fl/flmx-1-cre+ and the Tsc1fl/flmx-1-cre- (control [Ctrl]) mice with pIpC every other day for 2 wk to delete the Tsc1 gene, which is hereby referred to as KO in the figures. The pIpC treatment almost completely deleted the Tsc1 gene in the HSCs of the Tsc1fl/flmx-1-cre+ mice, as the Tsc1 transcripts in Flt2-Lin-Sca-1+c-Kit+ (FLSK) CD48- LT-HSCs (34) from Tsc1fl/flmx-1-cre+ mice were reduced by >500-fold at 10 d after the pIpC treatment (Fig. 1 a). In normal HSCs, mTOR activity is at a low level, as shown by flow cytometry of phosphorylated S6 (pS6), whereas in Tsc1 KO HSCs, the level of pS6 is increased by approximately10-fold (Fig. 1 b). These data confirmed that Tsc1 is completely deleted and mTOR activity is significantly increased in HSCs of Tsc1fl/flmx-1-cre+ mice after pIpC treatment.
###end p 13
###begin p 14
###xml 0 118 0 118 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Loss of Tsc1 drives HSCs from quiescence to rapid proliferation and results in increased frequency and number of HSCs.</bold>
###xml 123 127 123 127 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tsc1</italic>
###xml 180 185 180 185 <sup xmlns:xlink="http://www.w3.org/1999/xlink">fl/fl</sup>
###xml 193 194 193 194 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 176 194 176 194 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tsc1<sup>fl/fl</sup>mx-1-cre<sup>+</sup></italic>
###xml 212 217 212 217 <sup xmlns:xlink="http://www.w3.org/1999/xlink">fl/fl</sup>
###xml 225 226 225 226 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 208 226 208 226 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tsc1<sup>fl/fl</sup>mx-1-cre<sup>&#8722;</sup></italic>
###xml 352 353 352 353 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 779 780 775 776 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 952 957 936 941 <sup xmlns:xlink="http://www.w3.org/1999/xlink">fl/fl</sup>
###xml 965 966 949 950 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 948 966 932 950 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tsc1<sup>fl/fl</sup>mx-1-cre<sup>+</sup></italic>
###xml 977 982 961 966 <sup xmlns:xlink="http://www.w3.org/1999/xlink">fl/fl</sup>
###xml 990 991 974 975 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 973 991 957 975 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tsc1<sup>fl/fl</sup>mx-1-cre<sup>+</sup></italic>
###xml 1029 1034 1013 1018 <sup xmlns:xlink="http://www.w3.org/1999/xlink">fl/fl</sup>
###xml 1025 1042 1009 1026 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tsc1<sup>fl/fl</sup>mx-1-cre</italic>
###xml 1042 1043 1026 1027 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1168 1169 1152 1153 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1280 1283 1264 1267 <sup xmlns:xlink="http://www.w3.org/1999/xlink">low</sup>
###xml 1741 1742 1723 1724 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1831 1832 1813 1814 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1857 1858 1839 1840 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1981 1986 1961 1966 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tsc1-</italic>
###xml 2057 2058 2037 2038 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 2063 2064 2043 2044 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 2219 2220 2197 2198 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 2224 2225 2202 2203 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 2394 2399 2372 2377 <sup xmlns:xlink="http://www.w3.org/1999/xlink">fl/fl</sup>
###xml 2407 2408 2385 2386 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 2390 2408 2368 2386 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tsc1<sup>fl/fl</sup>mx-1-cre<sup>+</sup></italic>
###xml 2463 2468 2441 2446 <sup xmlns:xlink="http://www.w3.org/1999/xlink">fl/fl</sup>
###xml 2476 2477 2454 2455 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 2459 2477 2437 2455 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tsc1<sup>fl/fl</sup>mx-1-cre<sup>+</sup></italic>
###xml 2491 2496 2469 2474 <sup xmlns:xlink="http://www.w3.org/1999/xlink">fl/fl</sup>
###xml 2504 2505 2482 2483 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 2487 2505 2465 2483 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tsc1<sup>fl/fl</sup>mx-1-cre<sup>&#8722;</sup></italic>
###xml 2972 2973 2948 2949 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 2996 2997 2972 2973 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 195 199 <span type="species:ncbi:10090">mice</span>
###xml 1457 1461 <span type="species:ncbi:10090">mice</span>
###xml 1566 1570 <span type="species:ncbi:10090">Mice</span>
###xml 1961 1965 <span type="species:ncbi:10090">mice</span>
###xml 2106 2111 <span type="species:ncbi:10090">mouse</span>
###xml 2276 2280 <span type="species:ncbi:10090">mice</span>
Loss of Tsc1 drives HSCs from quiescence to rapid proliferation and results in increased frequency and number of HSCs. (a) Tsc1 is efficiently deleted in LT-HSCs. The 6-wk-old Tsc1fl/flmx-1-cre+ mice and the Tsc1fl/flmx-1-cre- littermates were treated with pIpC for 2 wk. At 10 d after completion of pIpC treatments, LT-HSCs, as defined by the FLSKCD48- phenotype, were sorted by FACS. mRNA levels were tested by real-time RT-PCR. Data shown have been normalized to HPRT. Data shown are means +/- SD of results from five independent experiments. (b) The pS6 level is up-regulated in Tsc1-deficient LT-HSCs measured by flow cytometry. The x axis shows the intensity of pS6 staining, and the y axis shows the cell number. (left) Representative FACS profiles. (right) Means +/- SD (n = 3) of mean fluorescence. The mean fluorescence intensity (MFI) is increased by approximately10-fold in the Tsc1-deficient HSCs. (c) RNA/DNA contents of the Ctrl and Tsc1fl/flmx-1-cre+ HSCs. Tsc1fl/flmx-1-cre+ HSCs are less quiescent than the Tsc1fl/flmx-1-cre- littermates, as measured by pyronin Y (RNA contents) and HOECHST (DNA contents) staining. (left) Dot plots of gated FLSKCD48- cells are shown (numbers indicate percentages). (right) The summary data of quiescent (percentage of pyronin Ylow cells) and the percentage of S, M, and G2M cells (>2n DNA contents) are shown. Data shown are means +/- SD of results from three independent experiments with a total of six mice per group. (d) Conditional deletion of the Tsc1 gene resulted in enhanced proliferation of the LT-HSCs. Mice were treated with pIpC as in panel a. BM cells were analyzed 24 h after BrdU labeling. (left) The histograms depict distributions of BrdU incorporation among the FLSKCD48- cells (numbers indicate percentages). (right) The bar graph shows the percentage of BrdU+ cells among the FLSKCD48- cells. Data shown are means +/- SD of results from three independent experiments, with a total of six mice per group. (e) Tsc1-deficient WBM and HSCs have increased apoptosis, indicated as Annexin V+ 7AAD-. (left) Representative profiles from one mouse per group are presented (numbers indicate percentages). (right) Means +/- SD of the percentage of Annexin V+7AAD- cells from four experiments with a total of eight mice per group are shown. (f) Sustained increase in the frequency and absolute number of HSCs in the pIpC-treated Tsc1fl/flmx-1-cre+ BM. At 10 and 30 d after pIpC treatments, BM from Tsc1fl/flmx-1-cre+ (KO) and Tsc1fl/flmx-1-cre- (Ctrl) littermates were stained with a panel of antibodies to identify LT-HSCs and short-term HSCs (ST-HSCs). (left) Data shown are FACS profiles depicting the increase in the frequency of HSCs on day 10 after completion of the pIpC treatment (numbers indicate percentages). (right) The bar graphs summarize the sustained increase in the frequency and number of HSCs on days 10 and 30 after pIpC treatment. Data shown are means +/- SD of results from three (day 30; n = 6) or five (day 10; n = 10) experiments.
###end p 14
###begin p 15
###xml 160 162 160 162 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib14">14</xref>
###xml 164 166 164 166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib35">35</xref>
###xml 347 355 347 355 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 c</xref>
###xml 418 419 406 407 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 458 461 446 449 <sup xmlns:xlink="http://www.w3.org/1999/xlink">low</sup>
###xml 527 532 515 520 <sup xmlns:xlink="http://www.w3.org/1999/xlink">fl/fl</sup>
###xml 540 541 528 529 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 523 541 511 529 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tsc1<sup>fl/fl</sup>mx-1-cre<sup>+</sup></italic>
###xml 587 590 575 578 <sup xmlns:xlink="http://www.w3.org/1999/xlink">low</sup>
###xml 649 650 637 638 <sub xmlns:xlink="http://www.w3.org/1999/xlink">0</sub>
###xml 440 444 <span type="species:ncbi:10090">mice</span>
###xml 542 546 <span type="species:ncbi:10090">mice</span>
It is proposed that one of the major functions of the hypoxic HSC niche is to keep HSCs quiescent and that the quiescence is critical to maintain the stemness (14, 35). Therefore, we tested the effect of mTOR activation on stem cell quiescence. First, we measured the total RNA/DNA contents in the LT-HSCs by pyronin/HOECHST staining. As shown in Fig. 1 c, at 10 d after pIpC treatment approximately70% of the FLSKCD48- LT-HSCs in the Ctrl mice are pyronin Ylow, consistent with their quiescent status. In the pIpC-treated Tsc1fl/flmx-1-cre+ mice, only <15% of the LT-HSCs were pyronin Ylow, which indicated that most of the LT-HSCs had exited the G0 phase. Judged by DNA contents, a significant increase in the proportion of S- and G2M-phase cells was also observed.
###end p 15
###begin p 16
###xml 85 93 85 93 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 d</xref>
###xml 154 159 154 159 <sup xmlns:xlink="http://www.w3.org/1999/xlink">fl/fl</sup>
###xml 167 168 167 168 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 150 168 150 168 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tsc1<sup>fl/fl</sup>mx-1-cre<sup>+</sup></italic>
###xml 302 314 302 314 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 (a&#8211;d)</xref>
###xml 330 334 330 334 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tsc1</italic>
###xml 169 173 <span type="species:ncbi:10090">mice</span>
###xml 272 276 <span type="species:ncbi:10090">mice</span>
Second, we measured the rate of HSC proliferation by BrdU incorporation, as shown in Fig. 1 d. At 10 d after pIpC treatment, nearly 60% of LT-HSCs in Tsc1fl/flmx-1-cre+ mice incorporated BrdU after 24 h of labeling, which is nearly fourfold as high as those from the Ctrl mice (13%). Thus, the data in Fig. 1 (a-d) indicated that Tsc1 deficiency drives HSCs from quiescence to rapid cell cycle.
###end p 16
###begin p 17
###xml 186 194 186 194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 e</xref>
###xml 223 227 223 227 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tsc1</italic>
###xml 263 271 263 271 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 e</xref>
###xml 384 389 384 389 <sup xmlns:xlink="http://www.w3.org/1999/xlink">fl/fl</sup>
###xml 397 398 397 398 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 380 398 380 398 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tsc1<sup>fl/fl</sup>mx-1-cre<sup>+</sup></italic>
###xml 405 413 405 413 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 f</xref>
###xml 598 603 598 603 <sup xmlns:xlink="http://www.w3.org/1999/xlink">fl/fl</sup>
###xml 611 612 611 612 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 594 612 594 612 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tsc1<sup>fl/fl</sup>mx-1-cre<sup>+</sup></italic>
###xml 664 672 664 672 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 f</xref>
###xml 399 403 <span type="species:ncbi:10090">mice</span>
###xml 613 617 <span type="species:ncbi:10090">mice</span>
By flow cytometry staining with Annexin V and 7-aminoactinomycin D, we observed that the levels of apoptosis among Ctrl HSCs is low (1%), as compared with that of the whole BM (WBM; 7%; Fig. 1 e). However, the apoptosis of Tsc1 KO HSCs was increased by >10-fold (Fig. 1 e). Overall, significant increases in both the frequency and number of HSCs were observed in the pIpC-treated Tsc1fl/flmx-1-cre+ mice (Fig. 1 f). Therefore, the increase in proliferation appeared to dominate over apoptosis. The increase of apoptosis may explain the reduction in the frequency and absolute number of HSCs in Tsc1fl/flmx-1-cre+ mice on day 30 when compared with those on day 10 (Fig. 1 f).
###end p 17
###begin title 18
Targeted mutation of TSC1 causes HSC-intrinsic defects in hematopoiesis
###end title 18
###begin p 19
###xml 73 78 73 78 <sup xmlns:xlink="http://www.w3.org/1999/xlink">fl/fl</sup>
###xml 86 87 86 87 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 69 87 69 87 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tsc1<sup>fl/fl</sup>mx-1-cre<sup>+</sup></italic>
###xml 374 382 362 370 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 a</xref>
###xml 447 451 435 439 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tsc1</italic>
###xml 558 563 546 551 <sup xmlns:xlink="http://www.w3.org/1999/xlink">fl/fl</sup>
###xml 571 572 559 560 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 554 572 542 560 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tsc1<sup>fl/fl</sup>mx-1-cre<sup>+</sup></italic>
###xml 706 714 694 702 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 b</xref>
###xml 882 890 870 878 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 c</xref>
###xml 88 92 <span type="species:ncbi:10090">mice</span>
###xml 352 356 <span type="species:ncbi:10090">mice</span>
###xml 573 577 <span type="species:ncbi:10090">mice</span>
Interestingly, despite the increase in HSC numbers, the pIpC-treated Tsc1fl/flmx-1-cre+ mice have an approximately50% reduction in white blood cell counts (P = 0.001) at 30 d after the pIpC treatment, as measured by a complete blood count (CBC) test, most of which are contributed by reduced lymphocytes. The counts of monocytes and RBCs in the mutant mice appeared normal (Fig. 2 a). To understand the hematopoiesis defects after the deletion of Tsc1, we analyzed a representation of multiple lineages of hematopoietic cells in the BM. We found that in Tsc1fl/flmx-1-cre+ mice, the BM cellularity is significantly reduced on day 10 of the pIpC treatments. The BM hypocellularity is more severe on day 30 (Fig. 2 b). Differentiated blood cells, such as B lymphocytes, myeloid cells, and erythroid cells, are also significantly reduced in the WBM compared with those in the Ctrl BM (Fig. 2 c).
###end p 19
###begin p 20
###xml 24 28 24 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tsc1</italic>
###xml 0 63 0 63 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Conditional deletion of <italic>Tsc1</italic> results in abnormal hematopoiesis.</bold>
###xml 81 86 81 86 <sup xmlns:xlink="http://www.w3.org/1999/xlink">fl/fl</sup>
###xml 94 95 94 95 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 77 95 77 95 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tsc1<sup>fl/fl</sup>mx-1-cre<sup>+</sup></italic>
###xml 113 118 113 118 <sup xmlns:xlink="http://www.w3.org/1999/xlink">fl/fl</sup>
###xml 126 127 126 127 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 109 127 109 127 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tsc1<sup>fl/fl</sup>mx-1-cre<sup>&#8722;</sup></italic>
###xml 170 176 170 176 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1</xref>
###xml 400 404 400 404 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tsc1</italic>
###xml 419 424 419 424 <sup xmlns:xlink="http://www.w3.org/1999/xlink">fl/fl</sup>
###xml 432 433 432 433 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 415 433 415 433 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tsc1<sup>fl/fl</sup>mx-1-cre<sup>+</sup></italic>
###xml 691 695 691 695 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tsc1</italic>
###xml 779 780 779 780 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 808 813 808 813 <sup xmlns:xlink="http://www.w3.org/1999/xlink">fl/fl</sup>
###xml 821 822 821 822 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 804 822 804 822 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tsc1<sup>fl/fl</sup>mx-1-cre<sup>+</sup></italic>
###xml 1036 1041 1034 1039 <sup xmlns:xlink="http://www.w3.org/1999/xlink">fl/fl</sup>
###xml 1049 1050 1047 1048 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1032 1050 1030 1048 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tsc1<sup>fl/fl</sup>mx-1-cre<sup>+</sup></italic>
###xml 1244 1249 1241 1246 <sup xmlns:xlink="http://www.w3.org/1999/xlink">fl/fl</sup>
###xml 1257 1258 1254 1255 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1240 1258 1237 1255 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tsc1<sup>fl/fl</sup>mx-1-cre<sup>+</sup></italic>
###xml 1295 1296 1292 1293 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1363 1364 1360 1361 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 1488 1489 1485 1486 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 96 100 <span type="species:ncbi:10090">mice</span>
###xml 434 438 <span type="species:ncbi:10090">mice</span>
###xml 635 639 <span type="species:ncbi:10090">mice</span>
###xml 832 836 <span type="species:ncbi:10090">mice</span>
###xml 958 962 <span type="species:ncbi:10090">mice</span>
Conditional deletion of Tsc1 results in abnormal hematopoiesis. The 6-wk-old Tsc1fl/flmx-1-cre+ mice and the Tsc1fl/flmx-1-cre- littermates were treated with pIpC, as in Fig. 1. (a) Reduced number of blood cells, as determined by CBC. The number in the littermate Ctrl is defined as 100%. LY, lymphocytes; MO, monocytes; NE, neutrophils and eosinophils. (b) Progressive loss of BM cellularity in the Tsc1-deficient Tsc1fl/flmx-1-cre+ mice. (c) Reduction of multiple lineages of differentiated leukocytes in the BM at 30 d after pIpC treatments. (d) Reduction of B lymphocytes but increase of erythrocytes in the spleens of Tsc1 mutant mice at 30 d after pIpC treatments. (e) Deletion of the Tsc1 gene caused extramedullary hematopoiesis in the spleen. (left) The number of FLSK48- HSCs in the spleens of Tsc1fl/flmx-1-cre+ and Ctrl mice 10 and 30 d after pIpC treatment. Data shown in a-e are means +/- SD of results from five experiments with a total of 10 mice per group. (middle) Hematoxylin and eosin staining of the spleens of Tsc1fl/flmx-1-cre+ and Ctrl littermates. The arrows indicate the high frequency of megakaryocytes. Bars, 20 mum. In five higher power fields, means of 49 and 7 megakaryocytes were found in spleen sections of Tsc1fl/flmx-1-cre+ and Ctrl littermates, respectively (n = 4). (f) Radioprotection by the Tsc1 mutant splenic HSCs. 20 x 106 spleen cells were injected into lethally irradiated recipients. The survival rates were compared by Kaplan-Meier analysis (n = 5).
###end p 20
###begin p 21
###xml 285 286 285 286 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 451 452 451 452 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 982 983 982 983 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1003 1004 1003 1004 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1053 1061 1053 1061 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 e</xref>
###xml 1173 1177 1173 1177 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tsc1</italic>
###xml 1308 1316 1308 1316 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 d</xref>
###xml 191 195 <span type="species:ncbi:10090">mice</span>
###xml 1120 1124 <span type="species:ncbi:10090">mice</span>
###xml 1185 1189 <span type="species:ncbi:10090">mice</span>
###xml 1246 1250 <span type="species:ncbi:10090">mice</span>
The BM hypocellularity could in theory be caused by increased apoptosis and/or defective proliferation. To evaluate the rate of proliferation of WT and KO BM in vivo, we pulsed the WT and KO mice with BrdU on day 10 after pIpC treatment and measured BrdU incorporation on total and Lin- BM cells 24 h after the pulse. As shown in Fig. S1 (available at ), the rate of BrdU incorporation was similar in WT and KO BM, regardless of whether the WBM or Lin- cells were compared. To determine whether TSC1 deletion impaired the colony formation activity of progenitor cells, we compared the WT and KO BM for the number and types of colonies formed in a standard CFU assay. As shown in Table S1, an increase of total colonies, including that of granulocyte erythroid macrophage and megakaryocyte, and macrophage colonies was observed. The size of colonies from the KO BM was also actually somewhat larger (not depicted). In contrast, the percentage of cells undergoing apoptosis (Annexin V+7-aminoactinomycin D-) was increased by almost fivefold in the KO BM (Fig. 1 e). Therefore, the paradoxical BM hypocellularity in the KO mice is likely caused by apoptosis. In the spleen of Tsc1 mutant mice, the B lymphocytes are reduced to half of those in Ctrl mice, whereas the erythroid cells are dramatically increased (Fig. 2 d).
###end p 21
###begin p 22
###xml 61 69 61 69 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 e</xref>
###xml 194 198 194 198 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tsc1</italic>
###xml 382 390 382 390 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 e</xref>
###xml 485 493 485 493 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 f</xref>
###xml 585 587 585 587 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib36">36</xref>
###xml 588 590 588 590 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib38">38</xref>
Interestingly, the numbers of megakaryocytes also increased (Fig. 2 e), which suggested extramedullary hematopoiesis. Consistent with this notion, a significant numbers of HSCs was found in the Tsc1-deficient spleen but not in Ctrl spleen. The increase in the number of spleen HSCs persisted on day 30 after pIpC treatment, although this was decreased compared with that on day 10 (Fig. 2 e). The HSCs in the Tsc1-deficient spleen rescued the lethally irradiated recipients for >9 mo (Fig. 2 f). However, because the HSCs have reduced self-renewal when their niche in BM is disrupted (36-38), it is unlikely that the HSCs in the spleen are fully functional. Furthermore, the KO splenocytes gave rise to more CFUs, including granulocyte erythroid macrophage and megakaryocyte colonies (Table S1).
###end p 22
###begin p 23
###xml 63 67 63 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tsc1</italic>
###xml 136 137 136 137 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 164 169 164 169 <sup xmlns:xlink="http://www.w3.org/1999/xlink">fl/fl</sup>
###xml 177 178 177 178 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 160 178 160 178 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tsc1<sup>fl/fl</sup>mx-1-cre<sup>+</sup></italic>
###xml 186 191 186 191 <sup xmlns:xlink="http://www.w3.org/1999/xlink">fl/fl</sup>
###xml 199 200 199 200 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 182 200 182 200 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tsc1<sup>fl/fl</sup>mx-1-cre<sup>&#8722;</sup></italic>
###xml 418 419 418 419 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 701 709 701 709 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 a</xref>
###xml 724 732 724 732 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 b</xref>
###xml 968 972 968 972 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tsc1</italic>
###xml 1011 1012 1011 1012 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1047 1055 1047 1055 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 c</xref>
###xml 1107 1111 1107 1111 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tsc1</italic>
###xml 1340 1348 1340 1348 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 d</xref>
###xml 201 205 <span type="species:ncbi:10090">mice</span>
###xml 607 611 <span type="species:ncbi:10090">mice</span>
We performed BM transplantation (BMT) to test the functions of Tsc1-deficient HSCs. In serial BMT rescue experiments, we transplanted 106 WBM cells from either Tsc1fl/flmx-1-cre+ or Tsc1fl/flmx-1-cre- mice without pIpC treatment into lethally irradiated congenic CD45.1 recipients. Then we treated the recipients with pIpC every other day for 2 wk. After 12 more weeks, we killed the recipients and transplanted 3 x 106 WBM cells from the recipients into a second group of lethally irradiated CD45.1 recipients. Stem-cell functions were determined by testing the survival and hematopoiesis of the recipient mice, and donor-type cell reconstitution in the recipient peripheral blood at 6 wk after BMT (Fig. 3 a). As shown in Fig. 3 b, although all second recipients of the Ctrl BMT survived, only five out of nine recipients of Tsc1-deficient BM did, even though three times as many BM cells were used for the second BMT. Among the live secondary BMT recipients of the Tsc1-deficient BM, the majority of the CD45+ cells were of the recipient type (Fig. 3 c). Consistent with a defective hematopoiesis of the Tsc1-deficient HSCs, the primary BMT recipients showed a drastic reduction in the white blood cells at 3 mo after completion of the pIpC treatments, with reduction in essentially all cell types analyzed, as measured by the CBC test (Fig. 3 d).
###end p 23
###begin p 24
###xml 4 8 4 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tsc1</italic>
###xml 0 49 0 49 <bold xmlns:xlink="http://www.w3.org/1999/xlink">The <italic>Tsc1</italic> deletion causes defective hematopoiesis.</bold>
###xml 154 159 154 159 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tsc1-</italic>
###xml 301 302 301 302 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 361 362 361 362 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 425 433 425 433 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 f</xref>
###xml 437 438 437 438 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 844 845 818 819 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 874 875 848 849 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 971 976 945 950 <sup xmlns:xlink="http://www.w3.org/1999/xlink">fl/fl</sup>
###xml 984 985 958 959 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 967 985 941 959 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tsc1<sup>fl/fl</sup>mx-1-cre<sup>+</sup></italic>
###xml 469 473 <span type="species:ncbi:10090">mice</span>
###xml 521 525 <span type="species:ncbi:10090">mice</span>
###xml 1140 1144 <span type="species:ncbi:10090">mice</span>
###xml 1243 1247 <span type="species:ncbi:10090">mice</span>
The Tsc1 deletion causes defective hematopoiesis. (a-d) Serial BMT reveals HSC-intrinsic defects. (a) Diagram of experimental design for data in b-d. (b) Tsc1-deficient BM cells are defective in rescuing lethally irradiated recipients in the second round, which indicate a reduced function of HSCs. 106 WBM cells were used for the first round of BMT, and 3 x 106 WBM cells were used for the second round of BMT. According to Fig. 1 f, 106 WBM cells from Tsc1-deficient mice contain approximately800 HSCs; those from Ctrl mice contain only approximately100 HSCs. For the WBM cells used for the second BMT, the frequency of HSCs was not analyzed. (c) Progressive loss of HSC activity as revealed by reduced replacement of recipient cells. Data shown are means +/- SD of the percentage of donor cells in the blood of recipients at 6 wk after BMT (n = 15 for the first BMT, and n = 9 for the second BMT). (d) Reduced reconstitution of multiple lineages of blood cells by Tsc1fl/flmx-1-cre+ BM. Data shown are means +/- SD of the relative number of cells in the blood, as measured by CBC. Data are normalized as the percentage of mean counts in mice reconstituted with WT BM. Summary data from two independent experiments involving a total of nine mice per group are presented. LY, lymphocytes; MO, monocytes; NE, neutrophils and eosinophils.
###end p 24
###begin p 25
###xml 198 206 198 206 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4 a</xref>
###xml 308 309 308 309 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 341 346 341 346 <sup xmlns:xlink="http://www.w3.org/1999/xlink">fl/fl</sup>
###xml 354 355 354 355 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 337 355 337 355 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tsc1<sup>fl/fl</sup>mx-1-cre<sup>+</sup></italic>
###xml 583 591 583 591 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4 b</xref>
###xml 700 704 688 692 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tsc1</italic>
###xml 1072 1076 1048 1052 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tsc1</italic>
A more accurate method to evaluate the function of HSCs is to compare them with WT BM cotransferred into the same recipients. We used this strategy in two different settings. First, as diagramed in Fig. 4 a, BM cells were isolated as soon as the pIpC treatments were completed. The 1:1 mixtures of the CD45.2+ donor-type (either Ctrl or Tsc1fl/flmx-1-cre+) and CD45.1 recipient-type WT BM were transplanted into lethally irradiated congenic CD45.1 recipients. The reconstitutions in the recipient peripheral blood were analyzed at 4 and 8 wk after BMT by flow cytometry. As shown in Fig. 4 b, Ctrl BM cells contribute approximately30% in the peripheral blood of recipients at 4 wk after BMT, whereas Tsc1-deficient BM cells only contribute <5% (P < 0.0001). At 8 wk after BMT, the percentage of peripheral blood from the Ctrl donors further increased to approximately50%, whereas that from the mutant donors is reduced to <1%. Such reduction is evident among all of the lineages checked, including B cells, T cells, and myeloid cells. Thus, competitive BMT indicates that Tsc1-deficient HSCs have severely reduced function.
###end p 25
###begin p 26
###xml 0 60 0 60 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Cell-intrinsic requirement for TSC1 in the function of HSCs.</bold>
###xml 71 75 71 75 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tsc1</italic>
###xml 528 529 526 527 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 587 591 585 589 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tsc1</italic>
###xml 739 744 737 742 <sup xmlns:xlink="http://www.w3.org/1999/xlink">fl/fl</sup>
###xml 750 751 748 749 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 735 751 733 749 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tsc1<sup>fl/fl</sup>MX-Cre<sup>+</sup></italic>
###xml 759 764 757 762 <sup xmlns:xlink="http://www.w3.org/1999/xlink">fl/fl</sup>
###xml 770 771 768 769 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 755 771 753 769 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tsc1<sup>fl/fl</sup>MX-Cre<sup>&#8722;</sup></italic>
###xml 860 864 858 862 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tsc1</italic>
###xml 934 935 930 931 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
Cell-intrinsic requirement for TSC1 in the function of HSCs. (a and b) Tsc1-deficient BM cells are dramatically less competent than WT BM cells in hematopoiesis when cotransferred into newly irradiated hosts. (a) The experimental designs. (b) The percentage of donor-type cells within the indicated populations at 4 or 8 wk after transplantation. Note that although the percentage of WT BM-derived cells progressively increased, those from Tsc-deficient BM reduced to background levels within 8 wk. Data shown are means +/- SD (n = 5) and have been repeated twice. (c and d) Deletion of Tsc1 after establishment of BMT reveals a cell-intrinsic and homing-independent role for Tsc1 in the function of HSCs. (c) Experimental design. The Tsc1fl/flMX-Cre+ or Tsc1fl/flMX-Cre- BM were mixed at 1:1 with recipient-type BM and transferred into irradiated recipients. Tsc1 deletion is induced at 6 wk after transplantation. (d) Means +/- SD (n = 5) of the percentage of donor-type cells in the blood at 4 or 8 wk after completion of pIpC treatments. The experiments have been repeated three times.
###end p 26
###begin p 27
###xml 65 69 65 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tsc1</italic>
###xml 154 158 154 158 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pten</italic>
###xml 175 176 175 176 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib6">6</xref>
###xml 178 180 178 180 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib25">25</xref>
###xml 244 249 244 249 <sup xmlns:xlink="http://www.w3.org/1999/xlink">fl/fl</sup>
###xml 257 258 257 258 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 240 258 240 258 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tsc1<sup>fl/fl</sup>mx-1-cre<sup>+</sup></italic>
###xml 496 500 496 500 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tsc1</italic>
###xml 517 522 517 522 <sup xmlns:xlink="http://www.w3.org/1999/xlink">fl/fl</sup>
###xml 530 531 530 531 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 513 531 513 531 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tsc1<sup>fl/fl</sup>mx-1-cre<sup>+</sup></italic>
###xml 558 566 558 566 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4 c</xref>
###xml 581 589 581 589 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4 d</xref>
###xml 723 728 723 728 <sup xmlns:xlink="http://www.w3.org/1999/xlink">fl/fl</sup>
###xml 736 737 736 737 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 719 737 719 737 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tsc1<sup>fl/fl</sup>mx-1-cre<sup>+</sup></italic>
###xml 746 751 746 751 <sup xmlns:xlink="http://www.w3.org/1999/xlink">fl/fl</sup>
###xml 759 760 759 760 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 742 760 742 760 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tsc1<sup>fl/fl</sup>mx-1-cre<sup>&#8722;</sup></italic>
###xml 846 851 846 851 <sup xmlns:xlink="http://www.w3.org/1999/xlink">fl/fl</sup>
###xml 859 860 859 860 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 842 860 842 860 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tsc1<sup>fl/fl</sup>mx-1-cre<sup>+</sup></italic>
###xml 888 889 888 889 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 921 922 921 922 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 948 949 948 949 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 951 959 951 959 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4 d</xref>
###xml 1295 1300 1295 1300 <sup xmlns:xlink="http://www.w3.org/1999/xlink">fl/fl</sup>
###xml 1308 1309 1308 1309 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1291 1309 1291 1309 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tsc1<sup>fl/fl</sup>mx-1-cre<sup>+</sup></italic>
###xml 1437 1441 1437 1441 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tsc1</italic>
###xml 1501 1505 1501 1505 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tsc1</italic>
###xml 351 355 <span type="species:ncbi:10090">mice</span>
###xml 761 765 <span type="species:ncbi:10090">mice</span>
A potential caveat of this experiment is that the defects in the Tsc1-deficient HSCs can be caused by improper homing into the BM, as was observed in the Pten-deficient HSCs (6, 25). To overcome this caveat, we mixed either the Ctrl or the Tsc1fl/flmx-1-cre+ BM at a 1:1 ratio with recipient-type BM and transferred the cells into lethally irradiated mice. 6 wk later, when the HSCs have properly homed and stably reconstituted the recipients, the recipients were treated with pIpC to delete the Tsc1 gene in the Tsc1fl/flmx-1-cre+ hematopoietic cells only (Fig. 4 c). As shown in Fig. 4 d, at 0 wk after completion of treatments, there was no significant difference in the reconstitution rate by donor-type cells from Tsc1fl/flmx-1-cre+ and Tsc1fl/flmx-1-cre- mice. At both 4 and 8 wk after the treatments, we observed drastic reductions of Tsc1fl/flmx-1-cre+ BM-derived leukocytes (CD45+), particularly in B cells (B220+) and myeloid cells (Mac-1+; Fig. 4 d). Reflecting a slower turnover of the host T cell compartment, a gradual increase in the Ctrl T cells was observed after pIpC treatment. In contrast, neither an increase nor a reduction of T cells was observed at 4 and 8 wk after pIpC treatments in Tsc1-deficient BMT. The lack of reduction is likely caused by slow turnover of theTsc1fl/flmx-1-cre+ T cells produced before the pIpC treatment. Collectively, these data clearly demonstrated that the HSC-intrinsic expression of Tsc1 is essential for leukogenesis, and that the requirement of Tsc1 is HSC intrinsic.
###end p 27
###begin title 28
Functional rescue of HSC by rapamycin
###end title 28
###begin p 29
###xml 135 140 135 140 <sup xmlns:xlink="http://www.w3.org/1999/xlink">fl/fl</sup>
###xml 148 149 148 149 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 131 149 131 149 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tsc1<sup>fl/fl</sup>mx-1-cre<sup>+</sup></italic>
###xml 315 323 315 323 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5 a</xref>
###xml 410 415 410 415 <sup xmlns:xlink="http://www.w3.org/1999/xlink">fl/fl</sup>
###xml 423 424 423 424 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 406 424 406 424 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tsc1<sup>fl/fl</sup>mx-1-cre<sup>+</sup></italic>
###xml 578 586 578 586 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5 b</xref>
###xml 715 723 715 723 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4 c</xref>
###xml 765 769 765 769 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tsc1</italic>
###xml 812 820 812 820 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5 c</xref>
###xml 159 163 <span type="species:ncbi:10090">mice</span>
###xml 425 429 <span type="species:ncbi:10090">mice</span>
###xml 740 744 <span type="species:ncbi:10090">mice</span>
Tsc1 is a known negative regulator for mTOR activity. To confirm the involvement of the mTOR pathway, we injected the pIpC-treated Tsc1fl/flmx-1-cre+ and Ctrl mice with rapamycin (4 mg per kilogram of bodyweight) every other day starting at the first pIpC treatment and continuing throughout the study. As shown in Fig. 5 a, the increase in the number of HSCs in both the BM and spleen of the pIpC-treated Tsc1fl/flmx-1-cre+ mice was completely inhibited by rapamycin. The number of B cells, myeloid cells, and, to a lesser extent, erythroid cells in the BM were also restored (Fig. 5 b). To confirm that rapamycin corrected the HSC-intrinsic, homing-independent defects, we repeated the BMT experiment depicted in Fig. 4 c and treated the mice with pIpC to delete Tsc1 in the presence of rapamycin. As shown in Fig. 5 c, rapamycin corrected the defects in all lineages of leukocytes. These data demonstrated that the TSC-mTOR pathway plays an essential role in the maintenance and in vivo functions of HSCs.
###end p 29
###begin p 30
###xml 0 93 0 93 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Hematopoietic functions of the Tsc1-deficient HSCs (cKO) are restored by rapamycin treatment.</bold>
###xml 205 209 205 209 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tsc1</italic>
###xml 237 242 237 242 <sup xmlns:xlink="http://www.w3.org/1999/xlink">fl/fl</sup>
###xml 248 249 248 249 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 233 249 233 249 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tsc1<sup>fl/fl</sup>MX-Cre<sup>+</sup></italic>
###xml 263 268 263 268 <sup xmlns:xlink="http://www.w3.org/1999/xlink">fl/fl</sup>
###xml 274 275 274 275 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 259 275 259 275 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tsc1<sup>fl/fl</sup>MX-Cre<sup>&#8722;</sup></italic>
###xml 730 735 730 735 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tsc1-</italic>
###xml 887 888 885 886 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1011 1015 1009 1013 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tsc1</italic>
###xml 1048 1056 1046 1054 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4 c</xref>
###xml 1437 1438 1433 1434 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 283 287 <span type="species:ncbi:10090">mice</span>
###xml 343 347 <span type="species:ncbi:10090">mice</span>
###xml 1030 1034 <span type="species:ncbi:10090">mice</span>
###xml 1226 1230 <span type="species:ncbi:10090">mice</span>
Hematopoietic functions of the Tsc1-deficient HSCs (cKO) are restored by rapamycin treatment. (a) Rapamycin inhibited expansion of HSCs in the BM and in the spleen and restored normal hematopoiesis in the Tsc1-deficient BM. 6-wk-old Tsc1fl/flMX-Cre+ (cKO) or Tsc1fl/flMX-Cre- (Ctrl) mice were treated with pIpC for 2 wk. At the same time, the mice were treated with either vehicle Ctrl of 4 mg/kg rapamycin every other day throughout the entire period of the study. The HSC numbers shown were LSK cells at day 10 after completion of pIpC treatment. Similar restorations were observed on day 30. At both time points, the numbers of LT-HSCs were also reduced to normal levels (not depicted). (b) Rapamycin restores hematopoiesis in Tsc1-deficient BM. The data are the number of different lineages of cells from the BM collected at 30 d after pIpC treatments. Data shown were means +/- SD (n = 4) from two independent experiments. (c) Rapamycin abrogates HSC-intrinsic functional defects caused by the deletion of Tsc1. The chimeric mice described in Fig. 4 c were treated with rapamycin, starting at the time of the pIpC treatment (4 mg/kg every other day, throughout the study). At 8 wk after completion of pIpC treatment, the mice were killed, and total and specific lineages of hematopoietic cells were analyzed by flow cytometry. Data shown are means +/- SD of the percentage of cells of donor origin from two independent experiments (n = 10).
###end p 30
###begin title 31
TSC1 maintains HSC function by repressing mitochondrion biogenesis and ROS production
###end title 31
###begin p 32
###xml 233 235 233 235 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib21">21</xref>
###xml 237 239 237 239 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib24">24</xref>
###xml 415 419 415 419 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tsc1</italic>
As an essential integrator of multiple intrinsic and extrinsic signals, the TSC-mTOR pathway has been linked to many different downstream pathways, including protein synthesis, autophagy, transcription, and mitochondrial metabolism (21, 24). Because quiescent cells typically have reduced energy metabolism, we hypothesized that increased mitochondrion functions may epitomize the lack of quiescence observed after Tsc1 deletion. We have produced several lines of evidence to substantiate this hypothesis.
###end p 32
###begin p 33
###xml 165 167 165 167 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib39">39</xref>
###xml 209 213 209 213 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tsc1</italic>
###xml 295 303 295 303 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6 a</xref>
###xml 416 421 416 421 <sup xmlns:xlink="http://www.w3.org/1999/xlink">fl/fl</sup>
###xml 429 430 429 430 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 412 430 412 430 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tsc1<sup>fl/fl</sup>mx-1-cre<sup>+</sup></italic>
###xml 468 476 468 476 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6 b</xref>
###xml 591 596 591 596 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cyt C</italic>
###xml 598 603 598 603 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cox5a</italic>
###xml 605 609 605 609 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ucp3</italic>
###xml 611 617 611 617 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Hdufs8</italic>
###xml 619 623 619 623 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ind3</italic>
###xml 629 635 629 635 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Atp5a1</italic>
###xml 671 675 671 675 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tsc1</italic>
###xml 692 700 692 700 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6 c</xref>
###xml 431 435 <span type="species:ncbi:10090">mice</span>
First, we measured the mitochondrion mass by flow cytometry with MitoTracker Green, which emits fluorescence only after binding to the mitochondrial lipid membrane (39). Our data demonstrated that >50% of the Tsc1-deficient HSCs had high mitochondrion contents, whereas <20% of the Ctrl HSC do (Fig. 6 a). By real-time PCR, we also found the number of mitochondrial DNA per HSC is almost doubled in pIpC-treated Tsc1fl/flmx-1-cre+ mice compared with that in the Ctrl (Fig. 6 b). Moreover, the transcripts of many mitochondrial genes that are involved in oxidative phosphorylation, including Cyt C, cox5a, Ucp3, Hdufs8, Ind3, and Atp5a1, are significantly up-regulated in Tsc1-deficient HSCs (Fig. 6 c).
###end p 33
###begin p 34
###xml 41 46 41 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tsc1-</italic>
###xml 65 66 65 66 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 0 72 0 72 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Up-regulated mitochondrial biogenesis in <italic>Tsc1-</italic>deficient, FLSKCD48<sup>&#8722;</sup> HSCs.</bold>
###xml 77 81 77 81 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tsc1</italic>
###xml 342 343 340 341 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 828 829 824 825 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 937 941 933 937 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tsc1</italic>
###xml 998 1003 994 999 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cyt C</italic>
###xml 1005 1010 1001 1006 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cox5a</italic>
###xml 1012 1016 1008 1012 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UCP3</italic>
###xml 1018 1024 1014 1020 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Hdufs8</italic>
###xml 1026 1031 1022 1027 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idh3a</italic>
###xml 1037 1043 1033 1039 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Atp5g1</italic>
###xml 1146 1147 1140 1141 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 245 250 <span type="species:ncbi:10090">mouse</span>
###xml 730 734 <span type="species:ncbi:10090">mice</span>
Up-regulated mitochondrial biogenesis in Tsc1-deficient, FLSKCD48- HSCs. (a) Tsc1 deletion results in increased mitochondrial biogenesis, as revealed by increased MitoTracker Green-high populations. (left) A representative FACS profile from one mouse BM LT-HSC is shown (numbers indicate percentages). (right) The summary data (means +/- SD; n = 4) of the percentage of cells with high mitochondrion contents are shown. (b) Relative mitochondrion DNA contents in WT and Tsc1-deficient LT-HSCs. Mitochondrial DNA and genomic DNA were extracted from HSCs, and the copy number of mitochondrial DNA was measured by RT-PCR, normalized to genomic DNA. As a Ctrl, the mitochondrial DNA copy numbers from the tails of the Ctrl and mutant mice are measured. The mean abundance in Ctrl HSCs was defined as 1. Data shown are means +/- SD (n = 3). (c) Up-regulation of the expressions of mitochondrial genes involved in oxidative phosphorylation in Tsc1-deficient HSCs. The mRNA levels of mitochondrial genes (Cyt C, Cox5a, UCP3, Hdufs8, Idh3a, and Atp5g1) are measured by real-time RT-PCR. Data shown were means +/- SD of the fraction of Hprt copy numbers (n = 4). The data presented in this figure have been reproduced in at least four experiments.
###end p 34
###begin p 35
###xml 356 360 356 360 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tsc1</italic>
###xml 469 477 469 477 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig7" ref-type="fig">Fig. 7 a</xref>
Second, mitochondrial oxidation may generate ROS. We therefore measured ROS levels in WT and Tsc1-deficient HSCs. 2',7'-dichlorodihydrofluorescein diacetate (DCF-DA) is an indicator of ROS levels because it is nonfluorescent until reacting with ROS inside the cells. In the Ctrl HSCs, ROS is repressed to very low levels. In contrast, the ROS level in the Tsc1-deficient HSCs was increased by approximately sevenfold, as indicated by flow cytometry of DCF-DA staining (Fig. 7 a).
###end p 35
###begin p 36
###xml 0 72 0 72 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Tsc1 maintains the function of HSCs by repressing the production of ROS.</bold>
###xml 81 85 81 85 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tsc1</italic>
###xml 264 265 262 263 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 438 442 436 440 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tsc1</italic>
###xml 840 841 836 837 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1005 1006 999 1000 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1072 1076 1066 1070 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tsc1</italic>
###xml 1281 1286 1275 1280 <sup xmlns:xlink="http://www.w3.org/1999/xlink">fl/fl</sup>
###xml 1281 1286 1275 1280 <italic xmlns:xlink="http://www.w3.org/1999/xlink"><sup>fl/fl</sup></italic>
###xml 1416 1424 1410 1418 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4 c</xref>
###xml 1639 1640 1633 1634 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1663 1664 1657 1658 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1683 1684 1677 1678 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1776 1777 1768 1769 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 453 457 <span type="species:ncbi:10090">mice</span>
###xml 886 890 <span type="species:ncbi:10090">mice</span>
###xml 1084 1088 <span type="species:ncbi:10090">mice</span>
###xml 1399 1403 <span type="species:ncbi:10090">mice</span>
Tsc1 maintains the function of HSCs by repressing the production of ROS. (a) The Tsc1-deficient HSCs show dramatically increased levels of ROS, as indicated by DCF-DA staining. (left) Data shown are overlays of a FACS profile. (right) Data shown are means +/- SD (n = 5) of the change in mean fluorescence after subtracting autofluorescences of HSCs. (b) ROS antagonist (NAC) treatment reduces the ROS level in Tsc1 mutant HSCs. Ctrl and Tsc1-deficient mice were treated with 1 mg/ml NAC in their drinking water in conjunction with pIpC treatment and were killed 10 d after the last pIpC injection. The BM cells were stained with HSC markers (FLSK) in conjunction with the ROS sensing dye DCF-DA. Data shown are relative levels of ROS. The mean fluorescence of untreated Ctrl HSCs is artificially defined as 1. Data shown are means +/- SD (n = 4). (c) The BM cellularity in Tsc1 mutant mice is significantly rescued by NAC treatment. The BM cells used were as described in b. Data shown are means +/- SD (n = 4). (d and e) The HSC frequency (d) and absolute number (e) in Tsc1 mutant mice were reduced to normal levels by NAC treatment. Results are as in b and c, except that the percentages and numbers of FLSK HSCs were analyzed. (f) In stable BM chimera consisting of WT and TSCfl/fl BM cells, the reconstitution capacity of Tsc1-deficient HSCs is significantly rescued by NAC treatment. Chimera mice depicted in Fig. 4 c were treated with NAC in their drinking water, starting at the same time of pIpC treatment. Blood samples were collected at the indicated time points and were analyzed by flow cytometry for the percentage of CD45.2+ donor cell types, B220+ B cells, and CD11b+ myeloid cells of donor type. Data shown are means +/- SD from two independent experiments (n = 10).
###end p 36
###begin p 37
###xml 28 30 28 30 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib26">26</xref>
###xml 32 34 32 34 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib40">40</xref>
###xml 35 37 35 37 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib42">42</xref>
###xml 120 124 120 124 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tsc1</italic>
###xml 143 144 143 144 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 343 347 343 347 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tsc1</italic>
###xml 458 466 458 466 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig7" ref-type="fig">Fig. 7 b</xref>
###xml 506 514 506 514 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig7" ref-type="fig">Fig. 7 c</xref>
###xml 537 545 537 545 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig7" ref-type="fig">Fig. 7 d</xref>
###xml 574 578 574 578 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tsc1</italic>
###xml 764 768 764 768 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tsc1</italic>
###xml 806 814 806 814 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig7" ref-type="fig">Fig. 7 e</xref>
###xml 236 240 <span type="species:ncbi:10090">mice</span>
###xml 589 593 <span type="species:ncbi:10090">mice</span>
ROS can be harmful to HSCs (26, 40-42). To test whether increased ROS is responsible for the lack of HSC function after Tsc1 deletion, we used N-acetylcysteine (NAC), a widely used antioxidant, to scavenge free radicals. We treated the mice with NAC in drinking water combined with pIpC treatment. 10 d after pIpC treatment, the ROS levels in Tsc1-deficient HSCs were repressed by NAC treatment, whereas those in Ctrl HSCs remained essentially undetectable (Fig. 7 b). The increases in both the frequency (Fig. 7 c) and absolute number (Fig. 7 d) of HSCs in the conditional Tsc1-deficient mice were largely abrogated by NAC treatment. Therefore, the increased ROS is likely an underlying cause for the increased proliferation of HSCs. NAC treatment also prevented Tsc1 deletion-induced BM hypocellularity (Fig. 7 e).
###end p 37
###begin p 38
###xml 36 40 36 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tsc1</italic>
###xml 103 111 103 111 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4 c</xref>
###xml 265 266 265 266 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 320 325 320 325 <sup xmlns:xlink="http://www.w3.org/1999/xlink">fl/fl</sup>
###xml 333 334 333 334 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 316 334 316 334 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tsc1<sup>fl/fl</sup>mx-1-cre<sup>+</sup></italic>
###xml 442 447 430 435 <sup xmlns:xlink="http://www.w3.org/1999/xlink">fl/fl</sup>
###xml 455 456 443 444 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 438 456 426 444 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tsc1<sup>fl/fl</sup>mx-1-cre<sup>+</sup></italic>
###xml 499 500 487 488 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 563 571 551 559 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig7" ref-type="fig">Fig. 7 f</xref>
###xml 623 627 611 615 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tsc1</italic>
To directly test the role of ROS in Tsc1-deficient HSCs, we performed competitive BMT, as diagramed in Fig. 4 c. The recipients were given NAC water in conjunction with pIpC treatments. At 4 and 8 wk after pIpC treatment, the reconstitution rate of the total CD45.2+ donor-type peripheral blood cells in NAC-treated Tsc1fl/flmx-1-cre+ BM recipients was approximately45%, which is comparable to that of Ctrl BM. In contrast, the untreated Tsc1fl/flmx-1-cre+ BM recipients have <10% of donor-type CD45+ cells. This is reflected in the rescue of all major lineages (Fig. 7 f). Therefore, NAC treatment, which inhibited ROS in Tsc1-deficient HSCs, restored the HSC in vivo functions. These data strongly indicate that ROS is a major target of the TSC-mTOR pathway in HSCs.
###end p 38
###begin title 39
DISCUSSION
###end title 39
###begin p 40
###xml 111 113 111 113 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib21">21</xref>
###xml 337 341 337 341 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tsc1</italic>
###xml 407 409 407 409 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib31">31</xref>
###xml 411 413 411 413 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib32">32</xref>
###xml 441 443 441 443 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib33">33</xref>
The mTOR pathway has emerged as a central regulator for cellular growth, differentiation, and energy response (21). However, despite the extensive use of the mTOR inhibitors for immune suppression, the function of mTOR in the hematopoietic system has not been analyzed genetically. In this paper, we showed that the targeted mutation of Tsc1, an essential and specific negative regulator of mTOR complex 1 (31, 32) (for review see reference 33), abrogated the quiescence and function of HSCs.
###end p 40
###begin title 41
Tsc1 as an essential negative regulator for the quiescence of HSCs
###end title 41
###begin p 42
###xml 30 34 30 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tsc1</italic>
###xml 73 80 73 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MX1-Cre</italic>
###xml 113 117 113 117 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tsc1</italic>
###xml 247 248 247 248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib6">6</xref>
###xml 250 252 250 252 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib25">25</xref>
###xml 294 298 294 298 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tsc1</italic>
###xml 433 437 433 437 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tsc1</italic>
###xml 131 135 <span type="species:ncbi:10090">mice</span>
Because germline mutations of Tsc1 are embryonically lethal, we used the MX1-Cre transgene to induce deletion of Tsc1 in the adult mice. Recent studies have demonstrated that this approach leads to a nearly complete deletion of genes in the HSCs (6, 25), as we have demonstrated in the case of Tsc1. Using pS6 protein as a marker for mTOR activation, our data demonstrated a dramatic elevation of mTOR activity in the HSCs after the Tsc1 deletion.
###end p 42
###begin p 43
###xml 227 228 227 228 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib1">1</xref>
###xml 229 230 229 230 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib6">6</xref>
###xml 494 498 494 498 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pten</italic>
###xml 517 518 517 518 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib6">6</xref>
###xml 520 522 520 522 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib25">25</xref>
###xml 650 652 650 652 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib31">31</xref>
###xml 654 656 654 656 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib32">32</xref>
###xml 821 824 821 824 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p21</italic>
###xml 877 878 877 878 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib5">5</xref>
###xml 897 900 897 900 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 893 900 893 900 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tsc1<sup>&#8722;/&#8722;</sup></italic>
###xml 1008 1011 1008 1011 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1004 1011 1004 1011 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tsc1<sup>&#8722;/&#8722;</sup></italic>
###xml 1052 1055 1052 1055 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p21</italic>
In conjunction with mTOR activation, we observed a massive increase in HSC proliferation, RNA synthesis, mitochondrial biogenesis, and the production of ROS. Although it has been well established that adult HSCs divide slowly (1-6), the pathway that keeps them in the G0 phase has been largely unclear. Our data demonstrate that the TSC-mTOR pathway plays an essential role in keeping HSC in G0 phase. Increased proliferation of the HSCs has also been observed after a targeted mutation of the Pten gene in the HSCs (6, 25). Because Pten is a negative regulator of the PI3K-AKT pathway, which in turn stimulates mTOR by inactivating the TSC complex (31, 32), it is likely that the inactivation of TSC1 is at least in part responsible for Pten-induced hyperproliferation of HSCs. On the other hand, a targeted mutation of p21 is also known to induce hyperproliferation of HSCs (5). Because the Tsc1-/- HSCs actually had slightly higher levels of p21 transcript (unpublished data), a lack of quiescence of Tsc1-/- HSCs cannot be caused by a reduction in p21 expression.
###end p 43
###begin title 44
###xml 88 92 <span type="species:ncbi:10090">mice</span>
Overactivation of mTOR alone is insufficient to cause hematological malignancies in the mice
###end title 44
###begin p 45
###xml 151 155 151 155 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pten</italic>
###xml 172 173 172 173 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib6">6</xref>
###xml 175 177 175 177 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib25">25</xref>
###xml 300 302 300 302 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib40">40</xref>
###xml 359 363 359 363 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pten</italic>
###xml 448 450 448 450 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib33">33</xref>
###xml 504 508 504 508 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tsc1</italic>
###xml 528 532 528 532 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pten</italic>
###xml 558 562 558 562 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pten</italic>
###xml 628 629 628 629 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib6">6</xref>
###xml 631 633 631 633 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib25">25</xref>
###xml 699 703 699 703 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tsc1</italic>
###xml 794 799 794 799 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tsc1-</italic>
###xml 863 867 863 867 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tsc1</italic>
###xml 990 994 990 994 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pten</italic>
###xml 1037 1041 1037 1041 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tsc1</italic>
###xml 1128 1130 1128 1130 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib33">33</xref>
###xml 1189 1193 1189 1193 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tsc1</italic>
###xml 1281 1285 1281 1285 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pten</italic>
###xml 689 693 <span type="species:ncbi:10090">mice</span>
###xml 950 954 <span type="species:ncbi:10090">mice</span>
###xml 1118 1126 <span type="species:ncbi:9606">patients</span>
Part of the phenotypes we presented in this paper, including the increased proliferation and lost functions, are consistent with those reported in the Pten-deficient HSCs (6, 25). Thus, even though it has been argued that the PI3K-Akt pathway regulates the HSCs mainly through FOXOs instead of mTOR (40), our data are consistent with the notion that in HSCs, Pten is also an upstream regulator of the TSC-mTOR pathway, as revealed in other models (33). However, there are significant differences between Tsc1-deficient HSCs and Pten-deficient HSCs. Although Pten deletion promotes severe myeloproliferative disease within days (6, 25), we did not observe leukemia or other malignancies in mice with Tsc1 deletion in HSCs. Nor did we observe a single case of leukemia in BMT recipients when the Tsc1-deficient BM was serially transplanted over a 1-yr period after Tsc1 deletion. Flow cytometry analysis also found no myeloid dysplasia, as reported in mice with a conditional deletion of the Pten gene (unpublished data). The inability of Tsc1 mutation to cause cancer is supported by a general lack of cancer among TSC patients (33). However, our data did not rule out the possibility that Tsc1 deletion can provide one of several genetic changes necessary for tumorigenesis in the Pten-deficient BM.
###end p 45
###begin p 46
###xml 146 148 146 148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib43">43</xref>
###xml 149 151 149 151 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib45">45</xref>
###xml 257 261 257 261 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pten</italic>
###xml 288 291 288 291 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tsc</italic>
###xml 301 303 301 303 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib46">46</xref>
###xml 336 340 336 340 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pten</italic>
###xml 467 469 467 469 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib44">44</xref>
###xml 576 580 576 580 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pten</italic>
###xml 588 592 588 592 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tsc1</italic>
It should be noted that the Pten protein resides in distinct cellular pools and can mediate functions other than regulating the TSC-mTOR pathway (43-45). In addition, because of the feedback of S6 kinase to insulin receptor substrate 1, Akt is activated by Pten deletion but inhibited in Tsc mutants (46). The transformation of HSCs by Pten deletion might also be explained by the nuclear functions of Pten to maintain chromosomal integrity and/or activation of Akt (44). It remains to be investigated which pathway explains the difference in phenotypes after the deletion of Pten versus Tsc1.
###end p 46
###begin title 47
An explanation for the requirement of stem cell niches and quiescence for maintaining the long-term function of HSCs
###end title 47
###begin p 48
###xml 224 226 224 226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib47">47</xref>
###xml 273 276 273 276 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tsc</italic>
###xml 486 491 486 491 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tsc1-</italic>
###xml 593 595 593 595 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib48">48</xref>
###xml 665 669 665 669 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tsc2</italic>
###xml 805 809 805 809 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tsc1</italic>
###xml 578 584 <span type="species:ncbi:8164">Suzuki</span>
Notably, previous studies on the quiescence of HSCs have been limited to cell-cycle regulation. Hyperproliferation by itself, however, does not necessarily inhibit stem cell function, as fetal HSCs do divide at a high rate (47). Our data provide a missing link between the Tsc-mTOR pathway and mitochondrial biogenesis, and up-regulation of genes involved in oxidative function in the HSCs. Perhaps because of unbalanced production and removal, ROS levels increased dramatically in the Tsc1-deficient HSCs, which we show to be responsible for defects in HSC function. Recently, Suzuki et al. (48) reported a very modest increase (7% over Ctrl) of ROS activity when Tsc2 mutants were ectopically expressed in COS cells, and argued that this gain of function relates to Rac activation but is independent of Tsc1 loss and is, therefore, presumably independent of mTOR activation. It remains to be tested whether the pathway uncovered in our study is unique for HSCs.
###end p 48
###begin p 49
###xml 46 48 46 48 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib26">26</xref>
###xml 50 52 50 52 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib40">40</xref>
###xml 53 55 53 55 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib42">42</xref>
Because the HSCs are highly sensitive to ROS (26, 40-42), they are not programmed to neutralize products associated with active metabolism. Therefore, our study provides a novel explanation on why HSCs must remain quiescent to maintain their "stemness."
###end p 49
###begin p 50
###xml 66 67 66 67 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 76 78 76 78 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib21">21</xref>
###xml 265 267 265 267 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib36">36</xref>
###xml 268 270 268 270 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib38">38</xref>
Because the mTOR pathway is regulated by glucose, nutrients, and O2 levels (21), it would be of great interest to determine whether abnormal mTOR activation is the underlying cause for the loss of quiescence in HSCs after disruption of the stem cell niche in vivo (36-38). In toto, our data suggest mTOR activation as a unifying explanation of the requirements of HSC niche and quiescence in HSC function.
###end p 50
###begin title 51
MATERIALS AND METHODS
###end title 51
###begin title 52
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
Mice.
###end title 52
###begin p 53
###xml 4 9 4 9 <sup xmlns:xlink="http://www.w3.org/1999/xlink">fl/fl</sup>
###xml 16 18 16 18 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib49">49</xref>
###xml 278 280 278 280 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib50">50</xref>
###xml 10 14 <span type="species:ncbi:10090">mice</span>
###xml 67 72 <span type="species:ncbi:9606">Women</span>
###xml 229 233 <span type="species:ncbi:10090">mice</span>
###xml 341 345 <span type="species:ncbi:10090">mice</span>
Tsc1fl/fl mice (49) were provided by D.J. Kwiatkowski (Brigham and Women's Hospital, Boston, MA) and were backcrossed for six generations onto the C57BL/6 background in the animal facility at the University of Michigan. Mx-1-cre mice were purchased from the Jackson Laboratory (50). Recipients in reconstitution assays were 8-wk-old B6ly5.2 mice from the National Cancer Institute. All procedures involving experimental animals were approved by the University Committee on the Use and Care of Animals at the University of Michigan.
###end p 53
###begin title 54
pIpC, rapamycin, and NAC treatment.
###end title 54
###begin p 55
###xml 134 136 134 136 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib51">51</xref>
###xml 56 60 <span type="species:ncbi:10090">Mice</span>
###xml 293 297 <span type="species:ncbi:10090">Mice</span>
pIpC (Sigma-Aldrich) was resuspended in PBS at 1 mg/ml. Mice received 15 mg/kg of pIpC every other day seven times by i.p. injection (51). Rapamycin (Sigma-Aldrich) was reconstituted in absolute ethanol at 10 mg/ml and diluted in 5% Tween-80 (Sigma-Aldrich) and 5% PEG-400 (Hampton Research). Mice received 4 mg/kg rapamycin by i.p. injection every other day. NAC (Sigma-Aldrich) was delivered through feeding water at 1 mg/ml.
###end p 55
###begin title 56
Flow cytometry.
###end title 56
###begin p 57
###xml 180 186 <span type="species:ncbi:9913">bovine</span>
BM cells were flushed by a 25-gauge needle from the long bones (tibias and femurs) with HBSS without calcium or magnesium (Invitrogen), supplemented with 2% heat-inactivated fetal bovine serum. Peripheral blood was obtained from the tail veins of recipients at the time points indicated in the figures, and RBCs were lysed by ammonium chloride/potassium bicarbonate buffer before staining.
###end p 57
###begin p 58
###xml 57 58 57 58 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 101 102 101 102 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 107 108 107 108 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 113 114 113 114 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 118 119 118 119 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 159 161 159 161 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib34">34</xref>
For flow cytometry and purification of HSCs, the FLSKCD48- phenotype is used for LT-HSCs, and the Lin-Sca-1+c-kit+CD48+ phenotype is used for short-term HSCs (34). Lineage markers included B220, CD3, Gr-1, Mac-1, and Ter119 (BD Biosciences). Flow cytometry analysis was performed on an LSR II (BD Biosciences), and FACS was performed on a FACSAria (BD Biosciences). All other antibodies were obtained from eBioscience.
###end p 58
###begin p 59
For pS6 staining, BM cells were stained with the surface markers and fixed with fix/permealization buffer (BD Biosciences), and then incubated with Alexa Fluor 488-conjugated pS6 antibodies (Cell Signaling Technology) for 2 h in ice. The samples were analyzed by flow cytometry after the removal of unbound antibodies.
###end p 59
###begin p 60
To determine the RNA/DNA content, fresh BM cells were stained with surface markers for HSCs and fixed in cold 70% ethanol overnight at -20degreesC. 4 mug/ml pyronin Y (Sigma-Aldrich) and 2 mug/ml HOECHST 33342 (Sigma-Aldrich) were stained for 30 min at 4degreesC.
###end p 60
###begin p 61
###xml 70 74 <span type="species:ncbi:10090">mice</span>
BrdU (BD Biosciences) was injected i.p. into adults at 100 mg/kg. The mice were then given 1 mg/ml BrdU water for 24 h and killed for analysis. BrdU staining was performed according to the producer's manual.
###end p 61
###begin p 62
MitoTracker Green (Invitrogen) was stained at 50 nM for 15 min at 37degreesC after staining of surface markers. ROS was measured by DCF-DA (Invitrogen) staining at 10 muM for 15 min at 37degreesC after staining of surface markers, according to the manufacturer's manual.
###end p 62
###begin title 63
BMT.
###end title 63
###begin p 64
###xml 19 23 <span type="species:ncbi:10090">mice</span>
8-wk-old recipient mice were lethally irradiated with a Cs-137 x-ray source delivering 180 rads per min, for a combined 1,100 rads, delivered >2 h apart. Donor WBM cells with or without competitive recipient-type WBM cells were transplanted into recipients through the retroorbital venous sinus 24 h after irradiation. Reconstitutions were measured by flow cytometry of peripheral blood from the recipient tail vein at the time points indicated in the figures.
###end p 64
###begin title 65
CFU assay.
###end title 65
###begin p 66
###xml 43 48 43 48 <sup xmlns:xlink="http://www.w3.org/1999/xlink">fl/fl</sup>
###xml 56 61 56 61 <sup xmlns:xlink="http://www.w3.org/1999/xlink">fl/fl</sup>
###xml 69 70 69 70 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 71 75 <span type="species:ncbi:10090">mice</span>
WBM cells or splenocytes isolated from Tsc1fl/fl or Tsc1fl/flmx-1-cre+ mice 10 d after pIpC treatment were plated into MethoCult GFM3434 (StemCell Technologies, Inc.) and cultured for 12 d before counting under a microscope (CKX31; Olympus).
###end p 66
###begin title 67
Statistics.
###end title 67
###begin p 68
###xml 216 217 216 217 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
The function of HSCs in the rescue of lethal irradiation was compared by a Kaplan-Meier survival analysis, and the p-value of the log-rank tests are provided either in the figures or in the figure legends. Student's t tests were used for all other analyses (*, P < 0.05; **, P < 0.01; ***, P < 0.001).
###end p 68
###begin title 69
Online supplemental material.
###end title 69
###begin p 70
###xml 143 144 143 144 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 82 86 <span type="species:ncbi:10090">mice</span>
###xml 164 168 <span type="species:ncbi:10090">mice</span>
Table S1 shows a colony-forming assay of WBM cells and splenocytes from WT and KO mice. Fig. S1 depicts BrdU incorporation of WBM cells and Lin- cells in WT and KO mice. Online supplemental material is available at .
###end p 70
###begin title 71
Supplementary Material
###end title 71
###begin title 72
[Supplemental Material Index]
###end title 72
###begin p 73
###xml 46 51 46 51 <sup xmlns:xlink="http://www.w3.org/1999/xlink">fl/fl</sup>
###xml 46 51 46 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink"><sup>fl/fl</sup></italic>
###xml 52 56 <span type="species:ncbi:10090">mice</span>
We thank Dr. David J. Kwiatkowski for the Tsc1fl/fl mice, Shenghui He and Dr. Mark Kiel for technical help and discussions, Todd Brown for editorial assistance, and Drs. Yuan Zhu, Jun-Lin Guan, and Jiandie Lin for critical reading of the manuscript and/or helpful discussions.
###end p 73
###begin p 74
This study is supported by grants from the National Institutes of Health, the United States Department of Defense, and the American Cancer Society, and a gift fund of the University of Michigan Comprehensive Cancer Center.
###end p 74
###begin p 75
The authors have no financial conflict of interest.
###end p 75

